ReviewCureus2026
Antipsychotics and Sleep Architecture: Where Does Lurasidone Fit?
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sleep disturbances are highly prevalent in schizophrenia, bipolar disorder, and other psychiatric disorders and are associated with increased symptom burden, impaired functioning, and reduced quality of life. Although second-generation antipsychotics frequently affect sleep, their effects vary according to receptor-binding profile and should not be viewed solely as a consequence of sedation. Lurasidone is distinguished by antagonism at D2, 5-HT2A, and 5-HT7 receptors with minimal affinity for histamine H1 and muscarinic M1 receptors, a pharmacologic profile associated with relatively low intrinsic sedation. This narrative review summarizes the neurobiology of sleep, examines receptor-based hypotheses through which lurasidone may influence sleep, and reviews the available preclinical and clinical evidence regarding its effects on sleep continuity and sleep architecture. Limited human evidence suggests that lurasidone may improve objective measures of sleep continuity, whereas preclinical findings suggest possible effects on rapid eye movement and non-rapid eye movement sleep. However, direct human evidence supporting modification of sleep architecture remains limited, and existing phase-advance data should not be interpreted as evidence of altered circadian physiology. Dedicated sleep studies remain few, and long-term data using polysomnography, actigraphy, circadian biomarkers, and validated measures of daytime functioning are lacking. Further comparative studies are needed to determine whether lurasidone provides clinically meaningful sleep-related benefits beyond improvements attributable to treatment of the underlying psychiatric disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.